找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Breast Cancer Chemosensitivity; Dihua Yu,Mien-Chie Hung Book 2007 The Editor(s) (if applicable) and The Author(s), under exclusive license

[復(fù)制鏈接]
樓主: 小費
21#
發(fā)表于 2025-3-25 05:29:30 | 只看該作者
22#
發(fā)表于 2025-3-25 10:55:50 | 只看該作者
Estrogen Receptors in Resistance to Hormone Therapy,omeostasis and receptor coregulator proteins. Additionally, the role of nonclassical ERα signaling through growth factor receptors and the subsequent downstream-initiated signaling, and the role of the progesterone receptors will be discussed.
23#
發(fā)表于 2025-3-25 11:48:19 | 只看該作者
24#
發(fā)表于 2025-3-25 17:24:23 | 只看該作者
Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance,ors even as a monomer..–. The binding of ErbB2 to other ErbB receptors results in increased signaling potency of the dimerized receptors through several means, including increased ligand affinity, increased coupling efficiency to signaling molecules, and decreased rate of receptor internalization..–.
25#
發(fā)表于 2025-3-25 22:11:09 | 只看該作者
Book 2007emotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment..
26#
發(fā)表于 2025-3-26 02:20:42 | 只看該作者
27#
發(fā)表于 2025-3-26 05:55:37 | 只看該作者
Overview of Resistance to Systemic Therapy in Patients with Breast Cancer,rld in 2002, with more than 1 million new cases. Despite advances in early detection and the understanding of the molecular bases of breast cancer biology, about 30% of patients with early-stage breast cancer have recurrent disease. To offer more effective and less toxic treatment, selecting therapi
28#
發(fā)表于 2025-3-26 12:22:23 | 只看該作者
29#
發(fā)表于 2025-3-26 15:13:47 | 只看該作者
Therapy-Induced Apoptosis in Primary Tumors,d by conventional and investigational cancer therapies in preclinical models. As a result, new therapeutic approaches that directly target key components of apoptotic pathways are either entering or will soon enter clinical trials in patients, raising hopes that the information gained from the precl
30#
發(fā)表于 2025-3-26 19:54:05 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-18 14:19
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
福贡县| 绥滨县| 罗山县| 高青县| 巴东县| 师宗县| 颍上县| 葵青区| 宝应县| 扬中市| 汉中市| 镇安县| 临高县| 延吉市| 繁峙县| 安泽县| 嘉禾县| 淮南市| 贡嘎县| 嵊泗县| 子长县| 临沭县| 岐山县| 上高县| 铜梁县| 三亚市| 大渡口区| 井冈山市| 佛冈县| 高台县| 景泰县| 西青区| 方山县| 抚松县| 锡林郭勒盟| 霍城县| 昌平区| 本溪| 库尔勒市| 温州市| 沁源县|